Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Reviva Pharmaceuticals Holdings Inc (RVPH)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.34-10.53%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for RVPH yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Secure sufficient financing to support RECOVER-2 trial | Reviva plans to start the RECOVER-2 Phase 3 trial in 2026. | Intact | no financing secured by 2026-06-30 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, speculative development-stage biotech rather than an established earnings compounder. The long-term thesis is intact, but confidence is low and management execution has been mixed.
The evidence does not provide a valuation level or a clear account of market expectations, so whether RVPH is cheap, fair, or expensive versus peers cannot be assessed. The priced-in evidence shows low fragility, but that does not resolve the company’s business and funding risks.
Near term, the company is likely to remain loss-making while it advances brilaroxazine and seeks funding. Cash increased through June 2026, but RECOVER-2 enrollment shifted to the first half of 2027 and remains financing-dependent. An elevated risk of a next-quarter earnings miss, volatile management execution, and a May earnings miss and listing-rule notice add uncertainty, despite an August earnings beat.
Over the next one to three years, the thesis hinges on whether RVPH secures enough financing to start RECOVER-2 and delivers meaningful trial progress. Patent and commercial-exclusivity work also matters, but the evidence shows no completed FDA alignment or patent milestone. Near term, guidance changes and broader Healthcare sector results are additional swing factors.
The multi-year view remains intact, but progress is limited and depends heavily on funding and clinical execution. Losses, an elevated near-term earnings risk, and low confidence make the outlook highly uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company is working to fix Nasdaq listing issues. |
| Under Pressure |
| delisting due to bid price failure |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Start RECOVER-2 Phase 3 trial in first half of 2026 | Reviva plans to start the RECOVER-2 Phase 3 trial in 2026. | Under Pressure | trial not started by 2026-06-30 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.67 → $-1.15 · observed estimates
$0.14B → $0.14B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-07-25 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-07-26 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-07-27 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-07-28 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-07-29 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-07-30 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-07-31 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-01 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-02 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-03 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-04 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-05 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-06 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-08 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-09 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-10 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-12 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-13 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-14 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-15 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-16 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-17 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-18 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-19 | $-1.67 | $137,297,000 | 1 / 1 |
| 2026-08-20 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-08-21 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-08-22 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-08-23 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-08-24 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-08-25 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-08-26 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-08-27 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-08-28 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-08-29 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-08-30 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-08-31 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-01 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-02 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-03 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-04 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-05 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-06 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-07 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-08 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-09 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-10 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-11 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-12 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-13 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-14 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-15 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-16 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-17 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-18 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-19 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-20 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-21 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-22 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-23 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-24 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-25 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-26 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-27 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-28 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-29 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-09-30 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-01 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-02 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-03 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-04 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-05 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-06 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-07 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-08 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-09 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-10 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-11 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-12 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-13 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-14 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-15 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-16 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-17 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-18 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-19 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-20 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-21 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-22 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-23 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-24 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-25 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-26 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-27 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-28 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-29 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-30 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-10-31 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-11-01 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-11-02 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-11-03 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-11-04 | $-1.15 | $137,297,000 | 1 / 1 |
| 2026-11-05 | $-1.15 | $137,297,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.